Acadian Asset Management’s Minerva Neurosciences NERV Stock Holding History

Acadian Asset Management’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28K	Sell	4,767 -5,812	-55%	-$33.3K	﹤0.01%	1917
2025 Q4	$42K	Sell	10,579 -6,837	-39%	-$25.4K	﹤0.01%	1820
2025 Q3	$36K	Hold	17,416	–	–	﹤0.01%	1687
2025 Q2	$29K	Hold	17,416	–	–	﹤0.01%	1544
2025 Q1	$29K	Hold	17,416	–	–	﹤0.01%	1500
2024 Q4	$38K	Hold	17,416	–	–	﹤0.01%	1493
2024 Q3	$46K	Sell	17,416 -7	-0%	-$20	﹤0.01%	1815
2024 Q2	$55K	Hold	17,423	–	–	﹤0.01%	1596
2024 Q1	$44K	Hold	17,423	–	–	﹤0.01%	1397
2023 Q4	$107K	Hold	17,423	–	–	﹤0.01%	1346
2023 Q3	$120K	Sell	17,423 -4,040	-19%	-$36.2K	﹤0.01%	1281
2023 Q2	$195K	Sell	21,463 -6,878	-24%	-$36.3K	﹤0.01%	1279
2023 Q1	$44K	Hold	28,341	–	–	﹤0.01%	1531
2022 Q4	$44K	Sell	28,341 -1,393	-5%	-$6.02K	﹤0.01%	1593
2022 Q3	$274K	Sell	29,734 -191,350	-87%	-$1.13M	﹤0.01%	1134
2022 Q2	$732K	Sell	221,084 -2	-0%	-$8	﹤0.01%	879
2022 Q1	$1.47M	Hold	221,086	–	–	0.01%	745
2021 Q4	$1.41M	Buy	221,086 +7,276	+3%	+$68.5K	0.01%	748
2021 Q3	$2.97M	Sell	213,810 -9,094	-4%	-$137K	0.01%	578
2021 Q2	$4.14M	Buy	222,904 +5,202	+2%	+$112K	0.02%	516
2021 Q1	$5.09M	Buy	217,702 +3,971	+2%	+$99.2K	0.02%	474
2020 Q4	$4M	Buy	213,731 +582	+0.3%	+$14.7K	0.02%	565
2020 Q3	$5.42M	Buy	213,149 +98,935	+87%	+$2.67M	0.02%	420
2020 Q2	$3.3M	Buy	114,214 +90,740	+387%	+$5.32M	0.01%	583
2020 Q1	$1.13M	Buy	23,474 +12,611	+116%	+$761K	0.01%	753
2019 Q4	$618K	Buy	10,863 +6,081	+127%	+$268K	﹤0.01%	1020
2019 Q3	$296K	Sell	4,782 -2,471	-34%	-$140K	﹤0.01%	1222
2019 Q2	$326K	Buy	7,253 +3,111	+75%	+$156K	﹤0.01%	1117
2019 Q1	$261K	Sell	4,142 -5,385	-57%	-$324K	﹤0.01%	1288
2018 Q4	$514K	Buy	9,527 +4,174	+78%	+$306K	﹤0.01%	894
2018 Q3	$538K	Buy	5,353 +1,345	+34%	+$101K	﹤0.01%	866
2018 Q2	$265K	Buy	4,008 +3,075	+330%	+$187K	﹤0.01%	1012
2018 Q1	$47K	Buy	+933	New	+$44.8K	﹤0.01%	1368

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

Acadian Asset Management's NERV Position: Q1 2026 in Review

Acadian Asset Management reduced its Minerva Neurosciences (NERV) stake by 55% in Q1 2026, selling an estimated $33.3K and leaving 4,767 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #1917.

Acadian Asset Management first reported a position in NERV in Q1 2018 and has held it in 33 quarters since. The position peaked at $5.42M in Q3 2020. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

Acadian Asset Management held 4,767 shares of Minerva Neurosciences worth $28K as of Q1 2026.
Acadian Asset Management sold 5,812 Minerva Neurosciences shares in Q1 2026, an estimated $33.3K.
Minerva Neurosciences made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1917 holding.
Acadian Asset Management first reported a position in Minerva Neurosciences in Q1 2018 and has held it in 33 quarters since.
Acadian Asset Management's Minerva Neurosciences position peaked at $5.42M in Q3 2020.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.